XOMA Royalty has acquired Mural Oncology for an undisclosed amount, a transaction that integrates Mural Oncology's advanced protein engineering platform and its portfolio of cytokine-based immunotherapies into XOMA's holdings. This corporate acquisition signifies XOMA Royalty's strategic expansion into novel cancer treatment modalities.
Mural Oncology specializes in developing new immunotherapies for cancer. The company leverages its industry-leading protein engineering capabilities, combined with expertise in cytokine biology and immune cell modulation, to create first and novel immunotherapies. Its mission centers on addressing the unmet needs of cancer patients for whom current immunotherapies are either ineffective or inaccessible, aiming to deliver meaningful clinical benefit across a broad spectrum of cancers, including tumor types previously resistant to such treatments.
The acquisition is strategically significant for XOMA Royalty, providing access to Mural Oncology's innovative pipeline of programs designed to broaden the potential and reach of cytokine-based immunotherapies. This move allows XOMA Royalty to incorporate Mural Oncology's specialized scientific capabilities and ongoing development efforts, aiming to advance promising therapies. Expected synergies include the potential acceleration of drug development programs and enhanced capabilities in the oncology sector.
Moving forward, the combined entity is anticipated to focus on driving Mural Oncology’s preclinical and clinical programs. This integration is poised to support continued research and development in cytokine-based immunotherapies, with the aim of advancing new treatment options for cancer patients and unlocking the broader value of immunotherapy.